CONy 2024 | Anti-amyloid therapy for Alzheimer’s disease: beyond the 18-month mark

Dorota Religa, MD, PhD, Karolinska Institutet, Solna, Sweden, highlights the limited duration of studies with anti-amyloid therapies, typically lasting around 18 months. Few patients have received treatment beyond this timeframe, meaning questions remain about the optimal duration. Deciding when to stop treatment is another challenge, as criteria for stopping are not well-defined. Dr Religa suggests a more flexible approach, making use of registry-based studies to monitor patient outcomes beyond the 18-month mark. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.